Paper Details

  1. Home
  2. Paper Details

Randomized, double-blind, placebo-controlled, clinic-initiated, Canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes. Canadian Cooperative Study Group.

Author: AokiF Y, GillM J, LaweeD, MartelA Y, SacksS L, SchlechW, SingerJ, TyrrellL D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 200 patients with recurrent genital herpes found that edoxudine 3% cream was effective in reducing viral shedding and time to healing, particularly for women. Edoxudine was well-tolerated but its long-term role in managing recurrent genital herpes requires further evaluation.
Paper Details　
Original Abstract of the Article :
Treatment for recurrent genital herpes using edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/164.4.665

データ提供：米国国立医学図書館（NLM）

Edoxudine 3.0% Cream: A Potential Treatment for Recurrent Genital Herpes

This clinical trial evaluated the efficacy of topical edoxudine 3% cream in treating recurrent genital herpes. The study involved a large cohort of patients and employed a rigorous randomized, double-blind, placebo-controlled design to assess the effectiveness of edoxudine. The authors also investigated the impact of edoxudine on viral shedding and the correlation between lesion tenderness and pain in patients with recurrent genital herpes.

Edoxudine's Potential in Reducing Viral Shedding

The research demonstrated that edoxudine 3% cream significantly reduced viral shedding in both men and women. This finding is important because it suggests that edoxudine may help to reduce the transmission of herpes simplex virus. The study also revealed that edoxudine was well-tolerated, further supporting its potential as a safe and effective treatment for recurrent genital herpes.

Managing Recurrent Genital Herpes

This research provides promising evidence for the potential of edoxudine 3% cream in managing recurrent genital herpes. The reduction in viral shedding and the overall well-tolerated nature of edoxudine suggest it may be a valuable tool for managing this common condition. While further research is needed to fully define the clinical role of edoxudine in treating recurrent genital herpes, this study offers encouraging insights.

Dr.Camel's Conclusion

This clinical trial delves into the fascinating world of herpes simplex virus and its impact on human health. The research provides valuable insights into the potential of edoxudine 3% cream as a treatment option for recurrent genital herpes. The study's rigorous design and substantial sample size contribute to the reliability of the findings, offering hope for those seeking effective management of this common viral infection.

Date :
  1. Date Completed 1991-10-22
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

1894930

DOI: Digital Object Identifier

10.1093/infdis/164.4.665

Related Literature

Article Analysis
・Effective treatment of genital herpes
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.